Michele Mercuri has not added Biography.
If you are Michele Mercuri and would like to personalize this page please email our Author Liaison for assistance.
Associations of extracranial carotid atherosclerosis progression with coronary status and risk factors in patients with and without coronary artery disease.
Circulation Oct, 2002 | Pubmed ID: 12379574
Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin.
Circulation Oct, 2002 | Pubmed ID: 12390953
Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients.
The American journal of cardiology Nov, 2002 | Pubmed ID: 12398959
Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging.
Circulation Dec, 2002 | Pubmed ID: 12460866
Radical-trapping activity, blood pressure, and carotid enlargement in women.
Hypertension Feb, 2003 | Pubmed ID: 12574097
Carotid arterial structure in patients with documented coronary artery disease and disease-free control subjects.
Circulation Mar, 2003 | Pubmed ID: 12615793
Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups.
Clinical cardiology Nov, 2003 | Pubmed ID: 14640465
The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
The American journal of cardiology Jan, 2004 | Pubmed ID: 14715336
Coronary artery calcium outperforms carotid artery intima-media thickness as a noninvasive index of prevalent coronary artery stenosis.
Arteriosclerosis, thrombosis, and vascular biology Aug, 2005 | Pubmed ID: 15947237
Blood leukocyte count is a risk factor for intima-media thickening and subclinical carotid atherosclerosis in middle-aged men.
Atherosclerosis Oct, 2006 | Pubmed ID: 16378612
The CD40/CD40 ligand system in the skin of patients with subacute cutaneous lupus erythematosus.
The Journal of rheumatology Dec, 2007 | Pubmed ID: 18050371
The association of myeloperoxidase promoter polymorphism with carotid atherosclerosis is abolished in patients with type 2 diabetes.
Clinical biochemistry May, 2008 | Pubmed ID: 18280811
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
American heart journal Oct, 2010 | Pubmed ID: 20934556
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
The New England journal of medicine Oct, 2013 | Pubmed ID: 23991658
Edoxaban versus warfarin in patients with atrial fibrillation.
The New England journal of medicine Nov, 2013 | Pubmed ID: 24251359
Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48.
European heart journal Jun, 2014 | Pubmed ID: 24302269
Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
Stroke; a journal of cerebral circulation Aug, 2014 | Pubmed ID: 24947287
Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial.
Journal of the American College of Cardiology Aug, 2014 | Pubmed ID: 25104527
Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†
European heart journal Feb, 2015 | Pubmed ID: 25687352
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Lancet Mar, 2015 | Pubmed ID: 25769357
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Lancet Mar, 2015 | Pubmed ID: 25769361
A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.
Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists Apr, 2015 | Pubmed ID: 25809373
A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
American heart journal May, 2015 | Pubmed ID: 25965706
SOBRE A JoVE
Copyright © 2024 MyJoVE Corporation. Todos os direitos reservados